BR112015006656A2 - composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos - Google Patents

composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos

Info

Publication number
BR112015006656A2
BR112015006656A2 BR112015006656-9A BR112015006656A BR112015006656A2 BR 112015006656 A2 BR112015006656 A2 BR 112015006656A2 BR 112015006656 A BR112015006656 A BR 112015006656A BR 112015006656 A2 BR112015006656 A2 BR 112015006656A2
Authority
BR
Brazil
Prior art keywords
compositions
treatment
methods
heart failure
diabetic patients
Prior art date
Application number
BR112015006656-9A
Other languages
English (en)
Other versions
BR112015006656A8 (pt
Inventor
Zhou Mingdong
Original Assignee
Zensun (Shanghai) Science & Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun (Shanghai) Science & Technology Limited filed Critical Zensun (Shanghai) Science & Technology Limited
Publication of BR112015006656A2 publication Critical patent/BR112015006656A2/pt
Publication of BR112015006656A8 publication Critical patent/BR112015006656A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K13/00—Sugars not otherwise provided for in this class
    • C13K13/002—Xylose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K13/00—Sugars not otherwise provided for in this class
    • C13K13/007—Separation of sugars provided for in subclass C13K

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015006656A 2012-10-08 2012-10-08 composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos BR112015006656A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/001353 WO2014056121A1 (en) 2012-10-08 2012-10-08 Compositions and methods for treating heart failure in diabetic patients

Publications (2)

Publication Number Publication Date
BR112015006656A2 true BR112015006656A2 (pt) 2018-11-13
BR112015006656A8 BR112015006656A8 (pt) 2020-01-21

Family

ID=50476845

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006656A BR112015006656A8 (pt) 2012-10-08 2012-10-08 composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos

Country Status (9)

Country Link
US (2) US10894815B2 (pt)
EP (1) EP2903632A4 (pt)
JP (1) JP6475623B2 (pt)
CN (2) CN104884077B (pt)
AU (1) AU2012392119B2 (pt)
BR (1) BR112015006656A8 (pt)
CA (1) CA2884051A1 (pt)
RU (1) RU2650635C2 (pt)
WO (1) WO2014056121A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
JP6568052B2 (ja) 2013-05-22 2019-09-04 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 心不全を治療するためのニューレグリンの徐放
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN111840517A (zh) * 2019-04-28 2020-10-30 上海泽生科技开发股份有限公司 神经调节蛋白用于长效预防、治疗或延迟心脏损伤的方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2000502682A (ja) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
EP1037625A4 (en) * 1997-11-10 2002-07-31 Sloan Kettering Inst Cancer PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS OF CANCER THERAPY USING ARSENIC TRIOXIDE OR MELARSOPROL
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
CN102232084B (zh) 2008-11-28 2014-05-28 上海泽生科技开发有限公司 纽兰格林及其用途
CN102231987A (zh) 2008-11-28 2011-11-02 上海泽生科技开发有限公司 纽兰格林和心脏干细胞
ES2748886T3 (es) 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
ES2575125T3 (es) * 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
WO2011011388A2 (en) * 2009-07-22 2011-01-27 Children's Medical Center Corporation Neuregulin induced regeneraton of heart muscle muscle
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN103127579B (zh) 2011-11-21 2017-06-16 上海泽生科技开发股份有限公司 便携式注射泵的驱动系统
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
JP6568052B2 (ja) 2013-05-22 2019-09-04 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 心不全を治療するためのニューレグリンの徐放
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN111388682A (zh) 2015-05-08 2020-07-10 上海泽生科技开发股份有限公司 cMLCK基因导入

Also Published As

Publication number Publication date
CA2884051A1 (en) 2014-04-17
AU2012392119B2 (en) 2018-07-26
CN104884077B (zh) 2019-02-12
RU2015116264A (ru) 2016-11-27
CN109276705A (zh) 2019-01-29
JP6475623B2 (ja) 2019-02-27
AU2012392119A1 (en) 2015-04-09
CN109276705B (zh) 2023-10-20
RU2650635C2 (ru) 2018-04-16
JP2015532293A (ja) 2015-11-09
EP2903632A4 (en) 2016-07-13
CN104884077A (zh) 2015-09-02
BR112015006656A8 (pt) 2020-01-21
US20210347840A1 (en) 2021-11-11
WO2014056121A1 (en) 2014-04-17
US20150284440A1 (en) 2015-10-08
US10894815B2 (en) 2021-01-19
EP2903632A1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
BR112015006656A2 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
MY149011A (en) Process for preparing a sugar product
MY160038A (en) Manufacturing method for sugar solution and device for same
WO2018105934A3 (ko) 사이코스의 효율적인 제조 방법
BRPI0500882A (pt) processo para fabricação de xilose de elevada pureza
WO2012067980A3 (en) Process for producing 2,3,3,3-tetrafluoropropene and a process for purifying 2-chloro-1,1,1,2-tetrafluoropropane
MY198086A (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
EA201101173A1 (ru) Способ фракционирования бетаинсодержащего раствора
WO2011139646A3 (en) Method for producing tetrafluoropropenes
BR112012012352A2 (pt) processo para produção de monossacarídeos
MY181082A (en) Method for preparing sugar, bioethanol or microbial metabolite from lignocellulosic biomass
BR112015031780A2 (pt) processo para a produção de grânulos de biomassa e açúcares a partir de biomassa celulósica, e processo para a produção de grânulos de biomassa a partir da biomassa celulósica
MX363821B (es) Conversión eficiente de alto rendimiento de monosacaridos en 5-(clorometil)-2-furaldehído.
CY1118025T1 (el) Διεργασια και εγκατασταση για την παραγωγη σακχαρωδων προϊοντων απο σταφυλια
HK1163659A1 (en) Process for the preparation of ajoene
DK2235195T3 (da) Fremgangsmåde til fremstilling af en sukkersaft fra lignocellulosisk biomasse med forbedret enzymgenvinding
BR112016022838A8 (pt) Método de processamento de uma corrente hemicelulósica aquosa e processos de produção de derivados de lactato
MX2018002830A (es) Proceso para la extraccion de silice.
WO2013064682A3 (en) Fermentation process for producing chemicals
BRPI0818236A2 (pt) Processos para produção e recuperação de ácido chiquímico
BR112012031086A2 (pt) intermediários de agomelatina e método de preparação dos mesmos
BR102012023867A2 (pt) Método de pré-tratamento para produzir açúcares solúveis em água a partir de material lignocelulósico
WO2015044659A3 (en) Treated waste products, methods of preparing them and using the same
WO2013028030A3 (ko) 발효액에서 1,4-디아미노부탄의 분리 및 정제하는 방법
WO2012115402A3 (en) Crystalline form of docetaxel and process for preparation thereof

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SENSUN (SHANGHAI) SCIENCE AND TECHNOLOGY, CO., LTD. (CN)

Owner name: SENSUN (SHANGHAI) SCIENCE AND TECHNOLOGY, CO., LTD

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: CIENCIA RELACIONADA COM O ART.229-C DA LPI (ANUENCIA PREVIA) (DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. ).

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements